open access

Online first
Short communication
Published online: 2022-11-23
Get Citation

Acute management of paroxysmal atrial fibrillation with beta blockers plus intrave-nous flecainide: A real-world Chios registry (BETAFLEC-CHIOS)

Athanasios Kartalis1, Dimitrios Afendoulis1, Maria Moutafi1, Petros Voutas1, Nikolaos Papagiannis1, Stefanos Garoufalis1, Nikolaos Kartalis1, Nikolaos Smyrnioudis1, Georgios Andrikopoulos2, Matthaios Didagelos3
DOI: 10.33963/KP.a2022.0267
·
Pubmed: 36446070
Affiliations
  1. Department of Cardiology, Skylitseio General Hospital of Chios, Chios, Greece
  2. Department of Cardiology, Henri Dunant Hospital, Athens, Greece
  3. 1st Department of Cardiology, AHEPA University General Hospital, Thessaloniki, Greece

open access

Online first
Short communication
Published online: 2022-11-23

Abstract

Not available

Abstract

Not available
Get Citation
Supp./Additional Files (1)
Supplementary material
Download
128KB
About this article
Title

Acute management of paroxysmal atrial fibrillation with beta blockers plus intrave-nous flecainide: A real-world Chios registry (BETAFLEC-CHIOS)

Journal

Kardiologia Polska (Polish Heart Journal)

Issue

Online first

Article type

Short communication

Published online

2022-11-23

Page views

67

Article views/downloads

32

DOI

10.33963/KP.a2022.0267

Pubmed

36446070

Authors

Athanasios Kartalis
Dimitrios Afendoulis
Maria Moutafi
Petros Voutas
Nikolaos Papagiannis
Stefanos Garoufalis
Nikolaos Kartalis
Nikolaos Smyrnioudis
Georgios Andrikopoulos
Matthaios Didagelos

References (7)
  1. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021; 42(5): 373–498.
  2. Aliot E, Capucci A, Crijns HJ, et al. Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation. Europace. 2011; 13(2): 161–173.
  3. Madrid AH, Moro C, Marín-Huerta E, et al. Comparison of flecainide and procainamide in cardioversion of atrial fibrillation. Eur Heart J. 1993; 14(8): 1127–1131.
  4. Martı́nez-Marcos F, Garcı́a-Garmendia J, Ortega-Carpio A, et al. Comparison of intravenous flecainide, propafenone, and amiodarone for conversion of acute atrial fibrillation to sinus rhythm. The American Journal of Cardiology. 2000; 86(9): 950–953.
  5. Schnaubelt S, Domanovits H, Niederdoeckl J, et al. The Impact of the COVID-19 Pandemic on Incidences of Atrial Fibrillation and Electrical Cardioversion at a Tertiary Care Emergency Department: An Inter- and Intra-year Analysis. Front Med (Lausanne). 2020; 7: 595881.
  6. Ermakov S, Gerstenfeld EP, Svetlichnaya Y, et al. Use of flecainide in combination antiarrhythmic therapy in patients with arrhythmogenic right ventricular cardiomyopathy. Heart Rhythm. 2017; 14(4): 564–569.
  7. Wybraniec MT, Maciąg A, Miśkowiec D, et al. Efficacy and safety of antazoline for cardioversion of atrial fibrillation: propensity score matching analysis of a multicenter registry (CANT II Study). Pol Arch Intern Med. 2022; 132(6).

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73 , 80–180 Gdańsk, Poland

phone:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl